近年来，免疫疗法改变了非小细胞肺癌（NSCLC）的治疗策略，其中抗PD-1/PD-L1抗体应用最多。然而，大多数 NSCLC 患者并未从免疫检查点抑制剂 (ICIs) 中获益。血管异常是大多数实体瘤的标志，有助于免疫逃避。因此，联合抗血管生成疗法可能会提高抗 PD-1/PD-L1 抗体的有效性。本文阐述了抗血管生成药物联合抗PD-1/PD-L1抗体的作用机制，并对相关临床研究和预测性免疫治疗生物标志物进行了总结和分析，以期为NSCLC患者提供更多的治疗选择。 .版权所有 © 2023 何、王、徐、赵、白、王。

Immunotherapy has changed the treatment strategy of non-small cell lung cancer (NSCLC) in recent years, among which anti-PD-1/PD-L1 antibodies are the most used. However, the majority of patients with NSCLC do not derive benefit from immune checkpoint inhibitors (ICIs). Vascular abnormalities are a hallmark of most solid tumors and facilitate immune evasion. Thus, combining antiangiogenic therapies might increase the effectiveness of anti-PD-1/PD-L1 antibodies. In this paper, the mechanisms of anti-angiogenic agents combined with anti-PD-1/PD-L1 antibodies are illustrated, moreover, relevant clinical studies and predictive immunotherapeutic biomarkers are summarized and analyzed, in order to provide more treatment options for NSCLC patients.Copyright © 2023 He, Wang, Xu, Zhao, Bai and Wang.